Page 2 - Informa Pharma Intelligence News Today

Despite the prevalence and societal costs of pain in the United States, investment in pain medication development is low, due in part to poor understanding of the probability of successful development of such medications

New brand name Citeline reflects company transformation to focus on the global future of pharmaceutical and biopharmaceutical researchLONDON and NEW YORK, June 22, 2022. The rebrand follows leading global

Investegate announcements from Pharma Intelligence, Pharma Intelligence Unveils Its Rebrand to Citeline Following Transition to Independent Company

Rezolute faced a challenging task— to recruit pediatric patients for a clinical trial of an ultra-rare disease. In addition, Rezolute wanted to...

The psychedelic industry could revolutionize mental healthcare. Compounds like MDMA and psilocybin are rapidly being pushed through clinical trials and have already been embraced by numerous cities and states across the US. With the psychedelics gold rush upon us, experts are warning about the need for marketers to prioritize sober education over intoxicating profit.

New Report Highlights Key Industry Trends in Pharmaceutical R&DNEW YORK, April 28, 2022, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy.

Investegate announcements from Informa Business Intelligence, Informa Pharma Intelligence and The American Society of Gene & Cell Therapy (ASGCT) Launches Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC

Citeline Study Feasibility is a predictive analytics solution designed to help sponsors select the right countries, sites and investigators,...

Informa Pharma Intelligence announced the launch of its 30th Edition Pharma R&D Annual Review